pfizerto appeal over india drug patent refusal
Last Updated : GMT 05:17:37
Emiratesvoice, emirates voice
Emiratesvoice, emirates voice
Last Updated : GMT 05:17:37
Emiratesvoice, emirates voice

Pfizer : to appeal over India drug patent refusal

Emiratesvoice, emirates voice

Emiratesvoice, emirates voice Pfizer : to appeal over India drug patent refusal

New Delhi - AFP

US drug giant Pfizer said Friday it will appeal against an Indian ruling overturning a patent for a cancer drug, saying the decision raises questions about intellectual property protection in India. Indian generics heavyweight Cipla opposed the granting of the domestic patent for Prizer\'s Sutent, which is used to combat liver and kidney cancer. The patent office\'s decision went to the heart of India\'s patent act, which says a patent cannot be granted for a drug unless changes make it significantly more effective and innovative. \"The patentee (Pfizer) has miserably failed to demonstrate any improved activity\" warranting a patent, the patent office said in its decision. \"The invention that is claimed in the patent does not involve any inventive step... and hence (is) not patentable,\" Nilanjana Mukherjee, senior patent officer, said.A spokesman for Cipla, which revolutionised AIDS treatment by supplying cut-price drugs to the world\'s poor and which has been campaigning to be able offer other low-cost generic medicines, had no immediate comment. But Pfizer managing director Jazz Tobaccowalla said the company believes the ruling \"undermines intellectual property rights in India\". \"We will vigorously defend our basic Sutent patent,\" the Pfizer executive said in a statement, adding the company would appeal against the ruling to India\'s Intellectual Property Appellate Board. The patent decision marked another win by Cipla against a global pharmaceutical company. In September, a court threw out a patent infringement case launched against Cipla by Swiss drugmaker F. Hoffmann-La Roche over the Mumbai firm\'s version of a lung-cancer drug, ruling it had a different molecular makeup. The cases have been watched worldwide as they involve interpretation of stricter drug patent protection rules introduced by India in 2005 to comply with World Trade Organization regulations. India has some of the toughest criteria for drug companies to obtain patents, said D.G. Shah, secretary general of the Indian Pharmaceutical Alliance, an industry body. \"These rulings show (foreign) companies need to take into account that India will not permit tweaking of formulations for getting a patent. If they had those expectations, they were unrealistic,\" Shah told AFP. Medical charities have expressed concern compliance with WTO rules could reduce the country\'s role as a supplier of low-cost medicines. India is the world\'s leading exporter and manufacturer of non-branded medicines. But Western firms -- looking to countries such as India for sales growth -- have voiced criticism of brand protection in India. Earlier this year, an Indian ruling allowed a local firm to produce a vastly cheaper copy of German pharmaceutical giant Bayer\'s patented drug Nexavar for liver and kidney cancer. India\'s patents chief ruled the price Bayer charged was \"exorbitant\" and told the firm to give a \"compulsory licence\" -- permitted under WTO rules for public health reasons -- to Indian firm Natco Pharma to make a less costly version. Experts say that ruling could pave the way for a rush of other \"compulsory licence\" applications in India and other poor nations, allowing access to patented life-saving drugs at a fraction of the cost.

Name *

E-mail *

Comment Title*

Comment *

: Characters Left

Mandatory *

Terms of use

Publishing Terms: Not to offend the author, or to persons or sanctities or attacking religions or divine self. And stay away from sectarian and racial incitement and insults.

I agree with the Terms of Use

Security Code*

pfizerto appeal over india drug patent refusal pfizerto appeal over india drug patent refusal

 



Name *

E-mail *

Comment Title*

Comment *

: Characters Left

Mandatory *

Terms of use

Publishing Terms: Not to offend the author, or to persons or sanctities or attacking religions or divine self. And stay away from sectarian and racial incitement and insults.

I agree with the Terms of Use

Security Code*

pfizerto appeal over india drug patent refusal pfizerto appeal over india drug patent refusal

 



GMT 10:31 2014 Tuesday ,23 December

Mirages of failure: Lebanon cannot wait

GMT 10:08 2018 Wednesday ,24 January

Microsoft to open 4 data centres

GMT 21:41 2017 Tuesday ,31 October

Deaths, numerous injuries in New York crash

GMT 11:49 2016 Monday ,14 March

Palestinian wins $1m global teaching prize

GMT 07:57 2017 Monday ,04 December

Women take lead at contemporary dance festival

GMT 10:17 2011 Friday ,30 September

Yemeni star Arwa would not perform for free

GMT 09:27 2017 Thursday ,20 July

Dubai Municipality closes 94 food outlets

GMT 11:11 2017 Tuesday ,14 November

HRH Premier's patronage of Invest-in-Bahrain hailed

GMT 10:00 2017 Saturday ,11 February

No room for sentiment as Six Nations take shape

GMT 14:16 2017 Thursday ,13 July

Kittel maintains Tour sprint domination

GMT 09:52 2018 Wednesday ,17 January

Pretty dresses are no longer just

GMT 13:10 2018 Thursday ,11 January

Uproar in Hollywood over Williams-Wahlberg pay
 
 Emirates Voice Facebook,emirates voice facebook  Emirates Voice Twitter,emirates voice twitter Emirates Voice Rss,emirates voice rss  Emirates Voice Youtube,emirates voice youtube  Emirates Voice Youtube,emirates voice youtube

Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©

Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©

emiratesvoieen emiratesvoiceen emiratesvoiceen emiratesvoiceen
emiratesvoice emiratesvoice emiratesvoice
emiratesvoice
بناية النخيل - رأس النبع _ خلف السفارة الفرنسية _بيروت - لبنان
emiratesvoice, Emiratesvoice, Emiratesvoice